Open-Angle Glaucoma - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 74 Pages - SKU: GMD6776015
|
|
Open-Angle Glaucoma - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Open-Angle Glaucoma - Pipeline Review, H1 2012', provides an overview of the Open-Angle Glaucoma therapeutic pipeline. This report provides information on the therapeutic development for Open-Angle Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma. 'Open-Angle Glaucoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Open-Angle Glaucoma.
- A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Open-Angle Glaucoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Open-Angle Glaucoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Open-Angle Glaucoma Overview
- Therapeutics Development
- An Overview of Pipeline Products for Open-Angle Glaucoma
- Open-Angle Glaucoma Therapeutics under Development by Companies
- Open-Angle Glaucoma Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Open-Angle Glaucoma Therapeutics - Products under Development by Companies
- Open-Angle Glaucoma Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Open-Angle Glaucoma Therapeutics Development
- Alcon, Inc.
- Bausch & Lomb Incorporated
- Allergan, Inc.
- QLT Inc.
- Santen Incorporated
- Merck & Co., Inc.
- Santen Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Limited
- Inotek Pharmaceuticals Corporation
- Aerie Pharmaceuticals, Inc.
- Open-Angle Glaucoma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Saflutan - Drug Profile
- Saflutan - Drug Profile
- BOL-303259-X - Drug Profile
- INO-8875 - Drug Profile
- AR-12286 - Drug Profile
- HPP851 - Drug Profile
- Brinzolamide + Brimonidine - Drug Profile
- Bimatoprost + Brimonidine Tartrate + Timolol Maleate - Drug Profile
- AGN-207281 - Drug Profile
- Latanoprost - Drug Profile
- Latanoprost Punctal Plug Delivery System - Drug Profile
- AGN-210961 - Drug Profile
- AGN-210669 - Drug Profile
- OPA-6566 - Drug Profile
- DE-112 - Drug Profile
- AL-59412C - Drug Profile
- AL-54478 - Drug Profile
- DE-111 - Drug Profile
- NT-501 - Drug Profile
- Open-Angle Glaucoma Therapeutics - Drug Profile Updates
- Open-Angle Glaucoma Therapeutics - Discontinued Products
- Open-Angle Glaucoma Therapeutics - Dormant Products
- Open-Angle Glaucoma - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Open-Angle Glaucoma, H1 2012
- Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Development by Companies, H1 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2012
- Alcon, Inc., H1 2012
- Bausch & Lomb Incorporated, H1 2012
- Allergan, Inc., H1 2012
- QLT Inc., H1 2012
- Santen Incorporated, H1 2012
- Merck & Co., Inc., H1 2012
- Santen Pharmaceutical Co., Ltd., H1 2012
- Otsuka Pharmaceutical Co., Ltd., H1 2012
- Sun Pharmaceutical Industries Limited, H1 2012
- Inotek Pharmaceuticals Corporation, H1 2012
- Aerie Pharmaceuticals, Inc., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Open-Angle Glaucoma Therapeutics - Drug Profile Updates
- Open-Angle Glaucoma Therapeutics - Discontinued Products
- Open-Angle Glaucoma Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Open-Angle Glaucoma, H1 2012
- Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|